Mirzaten Q-Tab (Mirtazapine)

Mirtazapine increases the release of norepinephrine and serotonin by blocking presynaptic α2‑adrenergic receptors. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors and provides strong H1‑receptor blockade, which together produce antidepressant and sedative effects.

The appropriate dose of Mirzaten Q-Tab is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and decisions are made in consultation with a healthcare professional.

To place an order, submit an enquiry on the Mirzaten Q-Tab product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct mechanism involving α2‑adrenergic antagonism and H1‑receptor blockade, which often results in greater sedation and appetite stimulation. This profile can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirzaten Q-Tab tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect the tablets from moisture and direct sunlight to maintain product stability.

The tablet is taken orally, usually once daily in the evening or as directed by a healthcare provider. It should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include agranulocytosis or severe neutropenia, hypersensitivity reactions such as Stevens‑Johnson syndrome, significant hepatic dysfunction, and the emergence or worsening of suicidal thoughts, particularly during the early weeks of therapy.

Patients with known hypersensitivity to mirtazapine or any of its excipients, those currently taking monoamine oxidase inhibitors, or individuals with severe hepatic impairment should avoid Mirzaten Q-Tab unless a specialist determines that benefits outweigh risks.